AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Amneal Pharmaceuticals reported positive interim results from its Phase 4 ELEVATE-PD study. The first 55 patients showed significant improvements in daily Good On time, reductions in Off time, and improved motor symptom control after switching to CREXONT extended-release capsules. Amneal will present longer-term outcomes in 2026.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet